Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi is conducting a Phase 3 study titled A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis. The study aims to assess the effectiveness and safety of Duvakitug, a drug intended to treat ulcerative colitis, a chronic inflammatory bowel disease.
The study tests Duvakitug, administered via subcutaneous injection, across three different doses compared to a placebo. The goal is to determine the drug’s efficacy in maintaining remission in ulcerative colitis patients.
This interventional study is randomized, with participants assigned to parallel groups. It employs a quadruple masking approach, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary aim is treatment-focused.
The study began on September 15, 2025, with primary completion expected after 40 weeks, followed by a 240-week open-label extension. The last update was submitted on October 1, 2025, indicating ongoing recruitment.
Sanofi’s study could significantly impact its market position, potentially boosting investor confidence if Duvakitug proves effective. This development is crucial as Sanofi competes with other pharmaceutical companies in the ulcerative colitis treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.